[go: up one dir, main page]

US20160279087A1 - Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof - Google Patents

Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof Download PDF

Info

Publication number
US20160279087A1
US20160279087A1 US15/083,636 US201615083636A US2016279087A1 US 20160279087 A1 US20160279087 A1 US 20160279087A1 US 201615083636 A US201615083636 A US 201615083636A US 2016279087 A1 US2016279087 A1 US 2016279087A1
Authority
US
United States
Prior art keywords
tocotrienol
ethanolamide
dha
epa
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/083,636
Inventor
Steven C. Quay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
DRACOPHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DRACOPHARMA Inc filed Critical DRACOPHARMA Inc
Priority to US15/083,636 priority Critical patent/US20160279087A1/en
Publication of US20160279087A1 publication Critical patent/US20160279087A1/en
Assigned to ATOSSA THERAPEUTICS, INC. reassignment ATOSSA THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DRACOPHARMA, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a method utilizing a single administration or a unit dosage of omega-3 fatty acids and/or omega-3 fatty acid amides for the treatment of patients with dyslipidemias, including hypertriglyceridemia, high LDL-C serum levels, coronary heart disease (CHD), vascular disease, artherosclerotic disease, hypertension, and related conditions, and the prevention or reduction of cardiovascular and vascular events.
  • dyslipidemias including hypertriglyceridemia, high LDL-C serum levels, coronary heart disease (CHD), vascular disease, artherosclerotic disease, hypertension, and related conditions, and the prevention or reduction of cardiovascular and vascular events.
  • Cardiovascular diseases leading to morbidity and premature mortality are related to several risk factors such as hypertension, hypertriglyceridemia, hypercholesterolemia, high blood platelet aggregation and according to recent findings, a high activity of the blood coagulation factor VII phospholipid complex.
  • antihypertensive drugs have contributed to the decline in cardiovascular disease-related morbidity and mortality.
  • side effects and toxicity associated with the current antihypertensive therapy especially in the mildly hypertensive patient.
  • the pulse rate is coincidentally increased.
  • a drug with fewer adverse effects for the treatment of hypertension It would be particularly advantageous if such a drug could be used for the simultaneous treatment of all the above mentioned multiple risk factors associated with cardiovascular diseases, which is generally not the case with the currently available antihypertensive drugs.
  • flax seed oil has a typical composition as follows:
  • Each 1-gram capsule of this formulation which is commercialized as Lovaza® (GSK, Research Triangle Park, N.C. 27709), contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA—approximately 465 mg) and docosahexaenoic acid (DHA—approximately 375 mg).
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • Lovaza is reported to lower triglyceride levels 44.9% [Lovaza Package Insert, Table 2]. Unfortunately this formulation adversely affects low density lipoprotein cholesterol (LDL-C), increasing it by 44.5%. Patients are at an increased risk of cardiovascular diseases and events when their LDL-C increases.
  • LDL-C low density lipoprotein cholesterol
  • a first aspect of the invention is a method of treating high triglyceride and high LDL-C blood levels in a mammalian patient.
  • a therapeutically effective amount of omega-3 fatty acids and/or omega-3 fatty acid amides is administered in an acceptable carrier sufficient to lower both triglyceride and LDL-C blood levels.
  • the omega-3 fatty acids and/or omega-3 fatty acid amides include at least one of octadecatrienoic (ALA), eicosapentaenoic (EPA), or docosahexenoic (DHA) acid or ethanolamide. More preferably, the composition includes both EPA and DHA. These compositions can also be formulated with other lipid-lowering compounds, including statins, niacin-containing compounds, cholesterol-absorbing blockers, ethanolamine, and/or an HMG-CoA reductase inhibitor, including one or more tocotrienols.
  • the invention includes a method of synthesizing omega-3 fatty acid ethanolamides from fatty acid triglycerides. While the synthesis of fatty acid ethanolamides from the ethyl esters of EPA and DHA derived from plant sources (flax seed) and mackerel pike ( Cololabis sair ) has been described, the synthesis from omega-3 fatty acid triglycerides has not been described.
  • an orally administered fatty acid composition includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide); and at least one tocotrienol.
  • the composition has a total aerobic plate count per g/mL of less than 20,000 cfu.
  • the EPA ethanolamide is substantially in a range of 100 mg to 900 mg per dosage form
  • the DHA ethanolamide is substantially in a range of 100 mg to 900 mg per dosage form
  • the at least one tocotrienol is substantially in a range of 10 mg to 500 mg per dosage form.
  • the at least one tocotrienol includes at least one of ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol, or ⁇ -tocotrienol and is preferably substantially tocopherol-free.
  • the composition may be a medical food, a pharmaceutical preparation, or another oral formulation.
  • the orally administered fatty acid composition of the invention includes a capsule having approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg ⁇ -tocotrienol.
  • the capsule preferably has a gelatin base.
  • at least one of the EPA ethanolamide or the DHA ethanolamide may be synthesized from a respective fatty acid triglyceride.
  • a method of treating cardiovascular diseases includes the step of orally administering a therapeutically effective amount of a composition having 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol.
  • EPA ethanolamide 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide
  • DHA ethanolamide 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide
  • the EPA ethanolamide is substantially in a range of 100-900 mg per dosage form
  • the DHA ethanolamide is substantially in a range of 100-900 mg per dosage form
  • the at least one tocotrienol is substantially in a range of 10-500 mg per dosage form.
  • the at least one tocotrienol includes at least one of ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol, or ⁇ -tocotrienol and is preferably substantially tocopherol-free.
  • the orally administered composition may be a medical food, a pharmaceutical preparation, or other oral formulation.
  • the composition comprises a capsule having approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg ⁇ -tocotrienol.
  • the EPA ethanolamide, the DHA ethanolamide, and the at least one tocotrienol may be provided in a capsule having a gelatin base.
  • the method may optionally include the step of synthesizing at least one of the EPA ethanolamide or the DHA ethanolamide from a respective fatty acid triglyceride.
  • n-3 fatty acids are a family of unsaturated fatty acids that have in common a final carbon-carbon double bond in the n-3 position; that is, the third bond from the methyl end of the fatty acid.
  • This table lists several different names for the most common n-3 fatty acids found in nature.
  • the invention includes a preferably oral formulation (e.g., a pharmaceutical preparation or a medical food) of omega-3 fatty acid amides, including the ethanolamine amides.
  • the amides Unlike the ethyl esters or the triglycerides of omega-3 fatty acids, the amides have several beneficial effects without many of the concomitant negative effects.
  • the amides of omega-3 fatty acids boost production of phospholipids by, among other reasons, contributing both the ethanolamine head group and the fatty acid chains to phosphatidylethanolamine and phosphatidylcholine.
  • they are metabolized into substances that are typically in short supply in the human body: ethanolamine and omega-3 fatty acids.
  • amides of omega-3 fatty acids should not raise LDL cholesterol levels as do the ethyl esters and triglycerides of omega-3 fatty acids. Indeed, in the preferred embodiment, when combined with one or more tocotrienols, omega-3 fatty acid amides should advantageously lower both triglycerides and LDL cholesterol.
  • the invention also includes an oral formulation of omega-3 fatty acids and ethanolamine, preferably also including at least one tocotrienol.
  • Lipids can be extracted from flax seed and saira carcasses according to the literature method [E. G. Bligh and W. J. Dyer, Can. J. Biochem. Physiol., 37, No. 8, 911 (1959).].
  • the FA ethanolamides were purified over a Chemapol L silica-gel column (Kavalier, Czech Rep., 40-100 ⁇ m) using a stepped gradient of acetone in hexane (0 ⁇ 10%) calculated as 2 g of starting ethanolamides per 60 g silica gel. Yield 900 mg of purified FA ethanolamides (Rf 0.47) from saira fat and flax-seed oil as colorless oily liquids for every 2 g of starting mixture placed on the column.
  • FA ethanolamides can prophetically be synthesized directly from FA triglycerides, rather than from FA ethyl esters as described above.
  • the invention includes a method in which FA ethanolamides are to be prepared by aminolysis of the three ester bonds of the FA triglycerides by three mole equivalents of ethanolamine.
  • FA triglycerides are typically much less expensive than FA ethyl esters, and the overall process would entail far fewer steps than that described above.
  • the prophetic inventive method is expected to be less expensive, more convenient, and faster than previous methods.
  • FA triglycerides (6.56 g) can be treated with freshly distilled monoethanolamine (over KOH, 6.53 g, 1:5 mole ratio) and trifluoroacetic acid (10 ⁇ L).
  • the mixture can be sealed in an ampul, vigorously shaken, held for 2 h at 140° C., cooled to 25° C., and removed from the ampul.
  • the contents could be treated with CHCl 3 (10 mL) and aqueous HCl (10%) until the pH reaches 3.
  • the resulting mixture could be vigorously shaken.
  • the CHCl 3 layer could then be separated after layering.
  • the extraction could be repeated twice.
  • the CHCl 3 fractions could be combined, dried over anhydrous Na 2 SO 4 , and evaporated in vacuum at 40° C.
  • a yield of 6.67 g (6.54 g for FA triglycerides from flax-seed oil) as an opaque yellowish-orange oil containing 4.86 g (4.78 g for FA triglycerides from flax-seed oil) of FA ethanolamides could be found.
  • the degree of conversion is expected to be about 70%.
  • the purity of the FA ethanolamides can be monitored by TLC.
  • the FA ethanolamides can be purified over a Chemapol L silica-gel column (Kavalier, Czech Rep., 40-100 ⁇ m) using a stepped gradient of acetone in hexane (0 ⁇ 10%) calculated as 2 g of starting ethanolamides per 60 g silica gel.
  • a yield 900 mg of purified FA ethanolamides (Rf 0.47) from saira fat and flax-seed oil as colorless oily liquids for every 2 g of starting mixture placed on the column could be expected.
  • An analogous procedure could be performed using triglycerides of ⁇ -linolenic, eicosapentaenoic, and docosahexaenoic acids to afford FA ethanolamides of these FA (Rf 0.47) as oily liquids in yields of 33, 34, and 35 mg, respectively, for each 100 mg of FA triglycerides used in the reaction. All FA ethanolamides from pure FA triglycerides and from mixtures could be analyzed by HPLC-MS (APCI).
  • the active ingredients and the excipients can be weighed and homogenized on a high speed stirrer.
  • the mixture can then be then colloid milled and de-aerated in a stainless steel vessel ready for encapsulation.
  • the mixture can be filled in soft gelatin capsules of size 20 oblong (average weight 1.4 g) using a standard capsulation machine. It is preferred that the delta-tocotrienol be substantially tocopherol-free.
  • Natural tocotrienols exist in four different forms or isomers, named alpha-, beta-, gamma- and delta-tocotrienol, each which contain different number of methyl groups on the chromanol ring.
  • the major structural difference from tocopherol is through its unsaturated side chain that has three double bonds in its farnesyl isoprenoid tail.
  • the delta-tocotrienol can be replaced or accompanied with portions of the other three tocotrienols.
  • the above example can be prepared as a medical food, a pharmaceutical preparation, or other variations of preparations that are ingestible by or administrable to a mammal.
  • TAC Total aerobic plate count
  • delta-tocotrienol is included with the omega-3 fatty acid amides.
  • any combination of alpha-, beta-, gamma, and/or delta tocotrienol may also be included.
  • amides of DHA and EPA are used in the exemplary prophetic formulation
  • amides of other omega-3 fatty acids e.g., selected from the list appearing on Table I above
  • the ethanolamide amides of the omega-3 fatty acids are described, any other amine, whether primary or secondary, aliphatic or aromatic, can be substituted.
  • specific amounts of the amides of DHA and EPA are listed in the exemplary prophetic formulation above, the invention is not so limited; rather, substantially any therapeutically effective amount of these or other amides of omega-3 fatty acids may be incorporated into the formulation.
  • the inventive oral formulation may include omega-3 fatty acids and ethanolamine directly instead of omega-3 fatty acid amides (which would metabolize into omega-3 fatty acids and ethanolamine). At least one tocotrienol is preferably included in this formulation.
  • inventive composition should be orally administered in the form of pills, soft capsules or the like.
  • administration could also be through any other route where the active ingredients may be efficiently absorbed and utilized, e.g. intravenously, subcutaneously, rectally, vaginally, or possibly topically.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.

Description

    RELATED APPLICATIONS
  • Domestic priority is claimed from U.S. Provisional Patent Application No. 61/232,554 entitled “Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof,” filed Aug. 10, 2009, and from US Provisional Patent Application No. 61/288,587 entitled “Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof,” filed Dec. 21, 2009 the entireties of both of which are incorporated by reference herein.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to a method utilizing a single administration or a unit dosage of omega-3 fatty acids and/or omega-3 fatty acid amides for the treatment of patients with dyslipidemias, including hypertriglyceridemia, high LDL-C serum levels, coronary heart disease (CHD), vascular disease, artherosclerotic disease, hypertension, and related conditions, and the prevention or reduction of cardiovascular and vascular events.
  • 2. Description of Related Art
  • Cardiovascular diseases leading to morbidity and premature mortality are related to several risk factors such as hypertension, hypertriglyceridemia, hypercholesterolemia, high blood platelet aggregation and according to recent findings, a high activity of the blood coagulation factor VII phospholipid complex. Over the last four decades, antihypertensive drugs have contributed to the decline in cardiovascular disease-related morbidity and mortality. There is, however, heightened concern about side effects and toxicity associated with the current antihypertensive therapy, especially in the mildly hypertensive patient. There are results indicating that, although some antihypertensive agents are efficient in reducing blood pressure, the pulse rate is coincidentally increased. Thus, there is a need for a drug with fewer adverse effects for the treatment of hypertension. It would be particularly advantageous if such a drug could be used for the simultaneous treatment of all the above mentioned multiple risk factors associated with cardiovascular diseases, which is generally not the case with the currently available antihypertensive drugs.
  • During the late 1980s through the mid-1990s, numerous publications appeared which report that various dietary fish oil preparations containing omega-3 polyunsaturated fatty acids have the effect of lowering serum triglycerides and cholesterol.
  • There are currently over 40 different non-prescription, over-the-counter products containing omega-3 fatty acids, usually as triglycerides. In these formulations, the triglycerides are polydisperse, containing both saturated as well as unsaturated fatty acids. For example, flax seed oil has a typical composition as follows:
  • Poly
    Mono unsaturated
    Saturated unsaturated Alpha
    Capric Lauric Myristic Palmitic Stearic Oleic Linoleic Linolenic
    Unsat./Sat. Acid Acid Acid Acid Acid Acid Acid (ω6) Acid (ω3)
    Oil or Fat ratio C10:0 C12:0 C14:0 C16:0 C18:0 C18:1 C18:2 C18:3
    Flaxseed Oil 9.0 — — — 3 7 21 16 53

    In some cases the saturated fatty acids can interfere with the effects of the polyunsaturated omega-3 fatty acids.
  • U.S. Pat. Nos. 5,502,077 and 5,656,667, both to Breivik et al., describe a lipid-regulating agent, as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of this formulation, which is commercialized as Lovaza® (GSK, Research Triangle Park, N.C. 27709), contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA—approximately 465 mg) and docosahexaenoic acid (DHA—approximately 375 mg).
  • In patients with very high triglyceride levels (>500 mg/dL) Lovaza is reported to lower triglyceride levels 44.9% [Lovaza Package Insert, Table 2]. Unfortunately this formulation adversely affects low density lipoprotein cholesterol (LDL-C), increasing it by 44.5%. Patients are at an increased risk of cardiovascular diseases and events when their LDL-C increases.
  • There is therefore a need to provide the beneficial effects of omega 3-fatty acids in compositions and formulations that do not have the LDL-C raising effects of the prior art formulations but in fact lower both LDL-C and triglycerides.
    • SUMMARY OF THE INVENTION
  • It has been found that fatty acid compositions containing omega-3 fatty acid amides (rather than their ethyl esters), including the ethanolamine amides, in an acceptable formulation, not only lower abnormally high triglycerides but also cholesterol, in the form of LDL-C. Accordingly, a first aspect of the invention is a method of treating high triglyceride and high LDL-C blood levels in a mammalian patient. A therapeutically effective amount of omega-3 fatty acids and/or omega-3 fatty acid amides is administered in an acceptable carrier sufficient to lower both triglyceride and LDL-C blood levels. Preferably, the omega-3 fatty acids and/or omega-3 fatty acid amides include at least one of octadecatrienoic (ALA), eicosapentaenoic (EPA), or docosahexenoic (DHA) acid or ethanolamide. More preferably, the composition includes both EPA and DHA. These compositions can also be formulated with other lipid-lowering compounds, including statins, niacin-containing compounds, cholesterol-absorbing blockers, ethanolamine, and/or an HMG-CoA reductase inhibitor, including one or more tocotrienols.
  • In another aspect of the invention, the invention includes a method of synthesizing omega-3 fatty acid ethanolamides from fatty acid triglycerides. While the synthesis of fatty acid ethanolamides from the ethyl esters of EPA and DHA derived from plant sources (flax seed) and mackerel pike (Cololabis sair) has been described, the synthesis from omega-3 fatty acid triglycerides has not been described.
  • In one aspect of the invention, an orally administered fatty acid composition includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide); and at least one tocotrienol. The composition has a total aerobic plate count per g/mL of less than 20,000 cfu. Preferably, the EPA ethanolamide is substantially in a range of 100 mg to 900 mg per dosage form, the DHA ethanolamide is substantially in a range of 100 mg to 900 mg per dosage form, and the at least one tocotrienol is substantially in a range of 10 mg to 500 mg per dosage form.
  • The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free.
  • The composition may be a medical food, a pharmaceutical preparation, or another oral formulation.
  • Preferably, the orally administered fatty acid composition of the invention includes a capsule having approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The capsule preferably has a gelatin base. Additionally, at least one of the EPA ethanolamide or the DHA ethanolamide may be synthesized from a respective fatty acid triglyceride.
  • In another aspect of the invention, a method of treating cardiovascular diseases includes the step of orally administering a therapeutically effective amount of a composition having 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. Preferably, The EPA ethanolamide is substantially in a range of 100-900 mg per dosage form, the DHA ethanolamide is substantially in a range of 100-900 mg per dosage form, and the at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free. The orally administered composition may be a medical food, a pharmaceutical preparation, or other oral formulation.
  • Optionally, the composition comprises a capsule having approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA ethanolamide, the DHA ethanolamide, and the at least one tocotrienol may be provided in a capsule having a gelatin base. The method may optionally include the step of synthesizing at least one of the EPA ethanolamide or the DHA ethanolamide from a respective fatty acid triglyceride.
  • Definitions
  • n-3 fatty acids (popularly referred to as ω-3 fatty acids or omega-3 fatty acids) are a family of unsaturated fatty acids that have in common a final carbon-carbon double bond in the n-3 position; that is, the third bond from the methyl end of the fatty acid.
  • This table lists several different names for the most common n-3 fatty acids found in nature.
  • TABLE I
    Lipid
    Common name name Chemical name
    16:3 all-cis-7,10,13-
    (n-3) hexadecatrienoic acid
    α-Linolenic acid (ALA) 18:3 all-cis-9,12,15-
    (n-3) octadecatrienoic acid
    Stearidonic acid (STD) 18:4 all-cis-6,9,12,15-
    (n-3) octadecatetraenoic acid
    Eicosatrienoic acid (ETE) 20:3 all-cis-11,14,17-
    (n-3) eicosatrienoic acid
    Eicosatetraenoic acid (ETA) 20:4 all-cis-8,11,14,17-
    (n-3) eicosatetraenoic acid
    Eicosapentaenoic acid (EPA) 20:5 all-cis-5,8,11,14,17-
    (n-3) eicosapentaenoic acid
    Docosapentaenoic acid (DPA), 22:5 all-cis-7,10,13,16,19-
    Clupanodonic acid (n-3) docosapentaenoic acid
    Docosahexaenoic acid (DHA) 22:6 all-cis-4,7,10,13,16,19-
    (n-3) docosahexaenoic acid
    Tetracosapentaenoic acid 24:5 all-cis-9,12,15,18,21-
    (n-3) docosahexaenoic acid
    Tetracosahexaenoic acid 24:6 all-cis-6,9,12,15,18,21-
    (Nisinic acid) (rc-3) tetracosenoic acid
    • DETAILED DESCRIPTION OF THE INVENTION
  • A more detailed description of the invention will now be given. It should be understood that this description is exemplary in nature and in no way serves to limit the scope of the invention, which is defined by the claims appearing hereinbelow.
  • The invention includes a preferably oral formulation (e.g., a pharmaceutical preparation or a medical food) of omega-3 fatty acid amides, including the ethanolamine amides. Unlike the ethyl esters or the triglycerides of omega-3 fatty acids, the amides have several beneficial effects without many of the concomitant negative effects. First, the amides of omega-3 fatty acids boost production of phospholipids by, among other reasons, contributing both the ethanolamine head group and the fatty acid chains to phosphatidylethanolamine and phosphatidylcholine. Second, they are metabolized into substances that are typically in short supply in the human body: ethanolamine and omega-3 fatty acids. Further, amides of omega-3 fatty acids should not raise LDL cholesterol levels as do the ethyl esters and triglycerides of omega-3 fatty acids. Indeed, in the preferred embodiment, when combined with one or more tocotrienols, omega-3 fatty acid amides should advantageously lower both triglycerides and LDL cholesterol. In the alternative to providing an oral formulation of the amides of omega-3 fatty acids, the invention also includes an oral formulation of omega-3 fatty acids and ethanolamine, preferably also including at least one tocotrienol.
  • Below are described exemplary and prophetic processes for synthesizing omega-3 fatty acid amides.
    • 1. Lipid Extraction
  • Lipids can be extracted from flax seed and saira carcasses according to the literature method [E. G. Bligh and W. J. Dyer, Can. J. Biochem. Physiol., 37, No. 8, 911 (1959).].
  • 2. Synthesis of FA Ethanolamides from FA Ethyl Esters
  • The method of Karaulov et. al. (Synthesis of Fatty-Acid Ethanolamides from Linum catharticum Oils and Cololabis sairsa Fats, Chemistry of Natural Compounds, Vol. 40, No. 3, 2004), repeated here, can be used. In the reference, a mixture of FA ethyl esters (6.56 g) was treated with freshly distilled monoethanolamine (over KOH, 6.53 g, 1:5 mole ratio) and trifluoroacetic acid (10 μL). The mixture was sealed in an ampul, vigorously shaken, held for 2 h at 140° C., cooled to 25° C., and removed from the ampul. The contents were treated with CHCl3 (10 mL) and aqueous HCl (10%) until the pH was 3. The resulting mixture was vigorously shaken. The CHCl3 layer was separated after layering. The extraction was repeated twice. The CHCl3 fractions were combined, dried over anhydrous Na2SO4, and evaporated in vacuum at 40° C. to constant mass. Yield 6.67 g (6.54 g for FA ethyl esters from flax-seed oil) as an opaque yellowish-orange oil containing 4.86 g (4.78 g for FA ethyl esters from flax-seed oil) of FA ethanolamides. The degree of conversion was about 70%. The purity of the FA ethanolamides was monitored by TLC. The FA ethanolamides were purified over a Chemapol L silica-gel column (Kavalier, Czech Rep., 40-100 μm) using a stepped gradient of acetone in hexane (0→10%) calculated as 2 g of starting ethanolamides per 60 g silica gel. Yield 900 mg of purified FA ethanolamides (Rf 0.47) from saira fat and flax-seed oil as colorless oily liquids for every 2 g of starting mixture placed on the column. An analogous procedure was performed using ethyl esters of α-linolenic, eicosapentaenoic, and docosahexaenoic acids to afford FA ethanolamides of these FA (Rf 0.47) as oily liquids in yields of 33, 34, and 35 mg, respectively, for each 100 mg of FA ethyl esters used in the reaction. All FA ethanolamides from pure FA ethyl esters and from mixtures were analyzed by HPLC-MS (APCI).
  • 3. Prophetic Synthesis of FA Ethanolamides from FA Triglycerides
  • In accordance with the invention, FA ethanolamides can prophetically be synthesized directly from FA triglycerides, rather than from FA ethyl esters as described above. Specifically, the invention includes a method in which FA ethanolamides are to be prepared by aminolysis of the three ester bonds of the FA triglycerides by three mole equivalents of ethanolamine. FA triglycerides are typically much less expensive than FA ethyl esters, and the overall process would entail far fewer steps than that described above. As such, the prophetic inventive method is expected to be less expensive, more convenient, and faster than previous methods.
  • FA triglycerides (6.56 g) can be treated with freshly distilled monoethanolamine (over KOH, 6.53 g, 1:5 mole ratio) and trifluoroacetic acid (10 μL). The mixture can be sealed in an ampul, vigorously shaken, held for 2 h at 140° C., cooled to 25° C., and removed from the ampul. The contents could be treated with CHCl3 (10 mL) and aqueous HCl (10%) until the pH reaches 3. The resulting mixture could be vigorously shaken. The CHCl3 layer could then be separated after layering. The extraction could be repeated twice. The CHCl3 fractions could be combined, dried over anhydrous Na2SO4, and evaporated in vacuum at 40° C. to constant mass. A yield of 6.67 g (6.54 g for FA triglycerides from flax-seed oil) as an opaque yellowish-orange oil containing 4.86 g (4.78 g for FA triglycerides from flax-seed oil) of FA ethanolamides could be found. The degree of conversion is expected to be about 70%. The purity of the FA ethanolamides can be monitored by TLC. The FA ethanolamides can be purified over a Chemapol L silica-gel column (Kavalier, Czech Rep., 40-100 μm) using a stepped gradient of acetone in hexane (0→10%) calculated as 2 g of starting ethanolamides per 60 g silica gel. A yield 900 mg of purified FA ethanolamides (Rf 0.47) from saira fat and flax-seed oil as colorless oily liquids for every 2 g of starting mixture placed on the column could be expected. An analogous procedure could be performed using triglycerides of α-linolenic, eicosapentaenoic, and docosahexaenoic acids to afford FA ethanolamides of these FA (Rf 0.47) as oily liquids in yields of 33, 34, and 35 mg, respectively, for each 100 mg of FA triglycerides used in the reaction. All FA ethanolamides from pure FA triglycerides and from mixtures could be analyzed by HPLC-MS (APCI).
    • 4. Exemplary Prophetic Preparation
  • One exemplary prophetic preparation could be as follows:
  • Soft gelatin capsules containing 1 g/per capsule
    • Composition:
  • EPA ethanolamide 525 mg/capsule
    DHA ethanolamide 315 mg/capsule
    Delta-tocotrienol 50 mg/capsule
    Gelatine 246 mg/capsule
    Glycerol 118 mg/capsule
    Red iron oxide 2.27 mg/capsule
    Yellow iron oxide 2.27 mg/capsule
  • The active ingredients and the excipients can be weighed and homogenized on a high speed stirrer. The mixture can then be then colloid milled and de-aerated in a stainless steel vessel ready for encapsulation. The mixture can be filled in soft gelatin capsules of size 20 oblong (average weight 1.4 g) using a standard capsulation machine. It is preferred that the delta-tocotrienol be substantially tocopherol-free. The tocotrienol (or TCT) group—together with tocopherols—compose the vitamin E family. Natural tocotrienols exist in four different forms or isomers, named alpha-, beta-, gamma- and delta-tocotrienol, each which contain different number of methyl groups on the chromanol ring. The major structural difference from tocopherol is through its unsaturated side chain that has three double bonds in its farnesyl isoprenoid tail. In the above example, the delta-tocotrienol can be replaced or accompanied with portions of the other three tocotrienols. The above example can be prepared as a medical food, a pharmaceutical preparation, or other variations of preparations that are ingestible by or administrable to a mammal.
  • 5. Standards and testing for microbial contamination of the oral solid dosage form of the instant inventive composition
  • The publication, “Microbial Bioburden on Oral Solid dosage Forms,” by Jose E. Martinez, Pharmaceutical Technolgy, February 2002, pages 58 to 70, is incorporated herein by reference. For formulations of the instant inventive composition, the water activity is 0.85, testing for TAC and USP indicator organisms is not necessary.
  • Furthermore, since formulations of the instant inventive composition also have water activity of 0.75, then no detailed microbiological testing of that product should be done.
    Total aerobic plate count (TAC) is an estimation of the total viable aerobic bacteria present in a sample of raw material, in-process material, or finished product. Samples are analyzed in accordance with the most current USP Guidelines Chapter <61>, Microbial Limits Test.
    Acceptable Total aerobic plate colonies (TAC) for OSDFs are established for the formulations of the inventive composition in terms of alert and action levels, which could be 1000 cfu g/mL and 10,000 cfu g/mL, respectively. A TAC that is 20,000 cfu g/mL is unacceptable.
    6. Testing of formulations of the instant inventive composition
  • The effects of the prior art formulations of U.S. Pat. No. 5,656,667 (LOVAZA) 4 g per day and of this invention can be assessed in randomized, placebo-controlled, double-blind, parallel-group studies of 84 adult patients (42 on LOVAZA, 42 on placebo) with very high triglyceride levels (Table 2). Patients whose baseline triglyceride levels are between 500 and 2,000 mg/dL can be enrolled in these studies which can have a 6 and 16 weeks' duration. The median triglyceride and LDL-C levels in these patients can be approximately 792 mg/dL and 100 mg/dL, respectively. Median HDL-C level can be about 23.0 mg/dL.
  • The changes in the major lipoprotein lipid parameters for the groups receiving LOVAZA or the changes expected from the exemplary prophetic formulation above are shown in Table II.
  • TABLE II
    Parameter Lovaza Change Exemplary Formulation Change
    Triglyceride Decrease 45% Expected Decrease about 45%
    LDL-Cholesterol Increase 45% Expected Decrease about 20%
  • The invention is not limited to the above description. For example, in the exemplary prophetic formulation, delta-tocotrienol is included with the omega-3 fatty acid amides. However, any combination of alpha-, beta-, gamma, and/or delta tocotrienol may also be included. Further, while amides of DHA and EPA are used in the exemplary prophetic formulation, amides of other omega-3 fatty acids (e.g., selected from the list appearing on Table I above) may be included in addition or in the alternative. While the ethanolamide amides of the omega-3 fatty acids are described, any other amine, whether primary or secondary, aliphatic or aromatic, can be substituted. Additionally, while specific amounts of the amides of DHA and EPA are listed in the exemplary prophetic formulation above, the invention is not so limited; rather, substantially any therapeutically effective amount of these or other amides of omega-3 fatty acids may be incorporated into the formulation.
  • Also, as mentioned above, the inventive oral formulation may include omega-3 fatty acids and ethanolamine directly instead of omega-3 fatty acid amides (which would metabolize into omega-3 fatty acids and ethanolamine). At least one tocotrienol is preferably included in this formulation.
  • Moreover, other additives, excipients, and the like may be added or used in the alternative. The actual commercialized product need not be a gelatin-based capsule; “dry” and vegetarian formulations may also be employed. Other variations are also contemplated. For example, the inventive composition should be orally administered in the form of pills, soft capsules or the like. However, the administration could also be through any other route where the active ingredients may be efficiently absorbed and utilized, e.g. intravenously, subcutaneously, rectally, vaginally, or possibly topically.
  • Having described certain embodiments of the invention, it should be understood that the invention is not limited to the above description. Rather, the scope of the invention is defined by the claims appearing hereinbelow and any equivalents thereof as would be appreciated by one of ordinary skill in the art.

Claims (2)

1-31. (canceled)
32. An orally administered fatty acid composition, comprising:
ethanolamine 5Z,8Z,11Z,14Z,17Z-eicosapentaenoate salt (ethanolamine EPA);
ethanolamine 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoate (ethanolamine DHA); and
at least one tocotrienol, wherein said composition has a total aerobic plate count per g/mL of less than 20,000 cfu.
US15/083,636 2009-08-10 2016-03-29 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof Abandoned US20160279087A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/083,636 US20160279087A1 (en) 2009-08-10 2016-03-29 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23255409P 2009-08-10 2009-08-10
US28858709P 2009-12-21 2009-12-21
US14/215,395 US9295658B2 (en) 2009-08-10 2014-03-17 Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof
US15/083,636 US20160279087A1 (en) 2009-08-10 2016-03-29 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/215,395 Continuation US9295658B2 (en) 2009-08-10 2014-03-17 Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof

Publications (1)

Publication Number Publication Date
US20160279087A1 true US20160279087A1 (en) 2016-09-29

Family

ID=43535008

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/852,620 Abandoned US20110033531A1 (en) 2009-08-10 2010-08-09 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
US13/761,243 Abandoned US20130149378A1 (en) 2009-08-10 2013-02-07 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
US14/215,395 Active US9295658B2 (en) 2009-08-10 2014-03-17 Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof
US15/083,636 Abandoned US20160279087A1 (en) 2009-08-10 2016-03-29 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US12/852,620 Abandoned US20110033531A1 (en) 2009-08-10 2010-08-09 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
US13/761,243 Abandoned US20130149378A1 (en) 2009-08-10 2013-02-07 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
US14/215,395 Active US9295658B2 (en) 2009-08-10 2014-03-17 Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof

Country Status (2)

Country Link
US (4) US20110033531A1 (en)
WO (1) WO2011019685A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5992926B2 (en) 2011-02-10 2016-09-14 ザ クリーブランド クリニック ファウンデーションＴｈｅ Ｃｌｅｖｅｌａｎｄ ＣｌｉｎｉｃＦｏｕｎｄａｔｉｏｎ Composition for the treatment and prevention of cardiovascular disease and thrombosis
CA2876177C (en) 2012-06-11 2022-06-14 The Cleveland Clinic Foundation Treatment and prevention of cardiovascular disease and thrombosis
CN103113253A (en) * 2013-01-28 2013-05-22 国家海洋局第三海洋研究所 Alcohol amine derivative of unsaturated fatty acid and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US20040102421A1 (en) * 2002-11-21 2004-05-27 Children's Hospital Research Center At Oakland Tocopherol and tocotrienol anti-inflammatory medicaments
US8586109B2 (en) * 2003-04-10 2013-11-19 American River Nutrition, Inc. Annatto extract compositions including tocotrienols and tocopherols and methods of use
US20070014866A1 (en) * 2005-07-15 2007-01-18 Curt Hendrix Composition for improving the efficacy and reducing the side effects of omega 3 fatty acids, fish oils and cardiovascular and diabetic treatments
CA2677253C (en) * 2007-02-01 2015-06-30 National Research Council Of Canada Formulations of lipophilic bioactive molecules
GB2459809A (en) * 2007-02-22 2009-11-11 Children S Hospital And Res Ct Fatty acid formulations and methods of use thereof
US20080305214A1 (en) * 2007-06-08 2008-12-11 Barilla G. E R. Fratelli S.P.A. Composition useful for the reduction of the cardiovascular risk and foods that contain it

Also Published As

Publication number Publication date
US9295658B2 (en) 2016-03-29
WO2011019685A2 (en) 2011-02-17
US20140200267A1 (en) 2014-07-17
US20110033531A1 (en) 2011-02-10
WO2011019685A3 (en) 2011-08-04
US20130149378A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
EP3735963B1 (en) Self-emulsifying composition of omega-3 fatty acid
EP3763364B1 (en) Self-emulsifying composition of omega-3 fatty acid
JP5827784B2 (en) Medicines and nutritional supplements containing vitamin K2
US5656667A (en) Fatty acid composition
JP2022121571A (en) Self-emulsifying composition of omega-3 fatty acids
EP2897595A2 (en) Omega -3 compositions
JP2019031555A (en) Composition
US20080160077A1 (en) Soft Gel Formulations
MX2011002640A (en) A polysaccharide capsule enclosing a fatty acid oil-containing emulsion.
WO2000023069A1 (en) Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiquinones and methods of using same
US20220288014A1 (en) Oral formulations of cannabis extracts and methods of making same
US9295658B2 (en) Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof
CA3195938A1 (en) Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
US20090143484A1 (en) Use of garlic oil to increase bioavailability of coenzyme q-10
JP2023546267A (en) Oral cannabinoid preparations comprising tocopheryl phosphate and long chain triglycerides or long chain fatty acids
WO2020083760A1 (en) Composition exhibiting enhanced oxidative stability

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ATOSSA THERAPEUTICS, INC., WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DRACOPHARMA, INC.;REEL/FRAME:064840/0792

Effective date: 20220706